478 related articles for article (PubMed ID: 33519714)
41. A retrospective evaluation of prognosis and cost-effectiveness of IVF in poor responders according to the Bologna criteria.
Busnelli A; Papaleo E; Del Prato D; La Vecchia I; Iachini E; Paffoni A; Candiani M; Somigliana E
Hum Reprod; 2015 Feb; 30(2):315-22. PubMed ID: 25432927
[TBL] [Abstract][Full Text] [Related]
42. In-vitro maturation of oocytes vs in-vitro fertilization with a gonadotropin-releasing hormone antagonist for women with polycystic ovarian syndrome: can superiority be defined?
Shavit T; Ellenbogen A; Michaeli M; Kartchovsky E; Ruzov O; Shalom-Paz E
Eur J Obstet Gynecol Reprod Biol; 2014 Aug; 179():46-50. PubMed ID: 24965979
[TBL] [Abstract][Full Text] [Related]
43. Fixed Gonadotropin-Releasing Hormone Antagonist Protocol
Dong M; Sun L; Huang L; Wang F; Zhang X; Liu F
Front Endocrinol (Lausanne); 2021; 12():690575. PubMed ID: 34867773
[TBL] [Abstract][Full Text] [Related]
44. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.
Toftager M; Bogstad J; Bryndorf T; Løssl K; Roskær J; Holland T; Prætorius L; Zedeler A; Nilas L; Pinborg A
Hum Reprod; 2016 Jun; 31(6):1253-64. PubMed ID: 27060174
[TBL] [Abstract][Full Text] [Related]
45. Assessing the adequacy of gonadotropin-releasing hormone agonist leuprolide to trigger oocyte maturation and management of inadequate response.
Chang FE; Beall SA; Cox JM; Richter KS; DeCherney AH; Levy MJ
Fertil Steril; 2016 Oct; 106(5):1093-1100.e3. PubMed ID: 27341988
[TBL] [Abstract][Full Text] [Related]
46. Live birth rate of gonadotropin-releasing hormone antagonist versus luteal phase gonadotropin-releasing hormone agonist protocol in IVF/ICSI: a systematic review and meta-analysis.
Liu C; Tian T; Lou Y; Li J; Liu P; Li R; Qiao J; Wang Y; Yang R
Expert Rev Mol Med; 2023 Dec; 26():e2. PubMed ID: 38095077
[TBL] [Abstract][Full Text] [Related]
47. Flexible GnRH Antagonist Protocol versus Progestin-primed Ovarian Stimulation (PPOS) Protocol in Patients with Polycystic Ovary Syndrome: Comparison of Clinical Outcomes and Ovarian Response.
Xiao ZN; Peng JL; Yang J; Xu WM
Curr Med Sci; 2019 Jun; 39(3):431-436. PubMed ID: 31209815
[TBL] [Abstract][Full Text] [Related]
48. Minimal ovarian stimulation is an alternative to conventional protocols for older women according to Poseidon's stratification: a retrospective multicenter cohort study.
Cozzolino M; Cecchino GN; Bosch E; Garcia-Velasco JA; Garrido N
J Assist Reprod Genet; 2021 Jul; 38(7):1799-1807. PubMed ID: 33851314
[TBL] [Abstract][Full Text] [Related]
49. A novel "delayed start" protocol with gonadotropin-releasing hormone antagonist improves outcomes in poor responders.
Cakmak H; Tran ND; Zamah AM; Cedars MI; Rosen MP
Fertil Steril; 2014 May; 101(5):1308-14. PubMed ID: 24636401
[TBL] [Abstract][Full Text] [Related]
50. Comparison of the GnRH agonist and antagonist protocol on the same patients in assisted reproduction during controlled ovarian stimulation cycles.
Lai Q; Zhang H; Zhu G; Li Y; Jin L; He L; Zhang Z; Yang P; Yu Q; Zhang S; Xu JF; Wang CY
Int J Clin Exp Pathol; 2013; 6(9):1903-10. PubMed ID: 24040457
[TBL] [Abstract][Full Text] [Related]
51. Evaluation of GnRH antagonist pretreatment before ovarian stimulation in a GnRH antagonist protocol in normal ovulatory women undergoing IVF/ICSI: a randomized controlled trial.
Zhang Y; Liu L; Qin J; Huang H; Xue L; Wang S; Tan W
Reprod Biol Endocrinol; 2021 Oct; 19(1):158. PubMed ID: 34641897
[TBL] [Abstract][Full Text] [Related]
52. A comparison of gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare protocols for poor responders undergoing in vitro fertilization.
Berin I; Stein DE; Keltz MD
Fertil Steril; 2010 Feb; 93(2):360-3. PubMed ID: 19131055
[TBL] [Abstract][Full Text] [Related]
53. Oocyte or embryo number needed to optimize live birth and cumulative live birth rates in mild stimulation IVF cycles.
Datta AK; Campbell S; Felix N; Singh JSH; Nargund G
Reprod Biomed Online; 2021 Aug; 43(2):223-232. PubMed ID: 34140227
[TBL] [Abstract][Full Text] [Related]
54. The effectiveness and safety of in vitro maturation of oocytes versus in vitro fertilization in women with a high antral follicle count.
Ho VNA; Braam SC; Pham TD; Mol BW; Vuong LN
Hum Reprod; 2019 Jun; 34(6):1055-1064. PubMed ID: 31111879
[TBL] [Abstract][Full Text] [Related]
55. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol.
Hohmann FP; Macklon NS; Fauser BC
J Clin Endocrinol Metab; 2003 Jan; 88(1):166-73. PubMed ID: 12519847
[TBL] [Abstract][Full Text] [Related]
56. Initiation of ovarian stimulation independent of the menstrual cycle: a case-control study.
Buendgen NK; Schultze-Mosgau A; Cordes T; Diedrich K; Griesinger G
Arch Gynecol Obstet; 2013 Oct; 288(4):901-4. PubMed ID: 23545834
[TBL] [Abstract][Full Text] [Related]
57. Progestin-primed ovarian stimulation is a feasible method for poor ovarian responders undergoing in IVF/ICSI compared to a GnRH antagonist protocol: A retrospective study.
Huang P; Tang M; Qin A
J Gynecol Obstet Hum Reprod; 2019 Feb; 48(2):99-102. PubMed ID: 30321608
[TBL] [Abstract][Full Text] [Related]
58. Reproductive outcomes after a single dose of gonadotropin-releasing hormone agonist compared with human chorionic gonadotropin for the induction of final oocyte maturation in hyper-responder women aged 35-40 years.
Tannus S; Turki R; Cohen Y; Son WY; Shavit T; Dahan MH
Fertil Steril; 2017 Jun; 107(6):1323-1328.e2. PubMed ID: 28501366
[TBL] [Abstract][Full Text] [Related]
59. Diminished ovarian reserve and poor response to stimulation in patients <38 years old: a quantitative but not qualitative reduction in performance.
Morin SJ; Patounakis G; Juneau CR; Neal SA; Scott RT; Seli E
Hum Reprod; 2018 Aug; 33(8):1489-1498. PubMed ID: 30010882
[TBL] [Abstract][Full Text] [Related]
60. Oral contraceptive pill, progestogen or oestrogen pretreatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques.
Farquhar C; Rombauts L; Kremer JA; Lethaby A; Ayeleke RO
Cochrane Database Syst Rev; 2017 May; 5(5):CD006109. PubMed ID: 28540977
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
